KRAS mutations play a vital role in controlling tumor metabolism, e.g., by stimulating glucose uptake [10,11,12], and an increased need for energy and elevated aerobic glycolysis are closely associated with chemoresistance, tumor progression, and metastasis of malignant tumors [13,14,15,16]. The gene discussed is KRAS; the disease is neoplasm.